Akebia Therapeutics (AKBA) Short term Debt (2018 - 2026)

Akebia Therapeutics (AKBA) has 5 years of Short term Debt data on file, last reported at $12.5 million in Q1 2026.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $12.5 million in Q1 2026; TTM through Mar 2026 was $12.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $17.5 million, down 45.31% from the prior year.
• Short term Debt for Q1 2026 stood at $12.5 million, down from $17.5 million in the prior quarter.
• Over the last five years, Short term Debt for AKBA reached as high as $98.2 million in Q2 2022 and fell as low as $8.0 million in Q3 2023.
• Historically, Short term Debt has averaged $42.2 million across 3 years, with a median of $24.0 million in 2023.
• On a YoY basis, Short term Debt climbed as much as 45.31% in 2023 and fell as far as 87.87% in 2023.
• Year by year, Short term Debt stood at $32.0 million in 2022, then sank by 45.31% to $17.5 million in 2023, then retreated by 28.6% to $12.5 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $12.5 million in Q1 2026, $17.5 million in Q4 2023, and $8.0 million in Q3 2023.